Literature DB >> 32031914

DATA 2000 waiver training for medical students: Lessons learned from a medical school experience.

Erin Zerbo1, Christin Traba2, Pravin Matthew3, Sophia Chen2, Bart K Holland4, Petros Levounis1, Lewis S Nelson5, Sangeeta Lamba5.   

Abstract

BACKGROUND: In the midst of this national opioid crisis, it has become apparent that there is a large shortage in the workforce of treatment providers equipped to deliver evidence-based care for opioid use disorders (OUD). Medications for opioid use disorder (MOUD), such as buprenorphine, are crucial in reducing mortality in those with OUD, and yet prescribers must meet federal waiver requirements under the Drug Addiction Treatment Act of 2000 (DATA 2000). There are now several pathways for medical schools to satisfy these waiver requirements for all graduates, but this has not yet become widespread. We propose that including a DATA 2000 waiver training within the medical school curriculum is a feasible and effective way to meet eligibility requirements to prescribe buprenorphine.
Methods: As part of a longitudinal opioid curriculum requirement, we implemented a DATA 2000 waiver training for all rising Year 4 medical students. One hundred sixty-nine students completed a hybrid (online and in-person) waiver training. The majority completed a pre- and post-survey.
Results: The pre-training survey showed 93% of rising Year 4 medical students (112/120) reported participation in care of patients with OUD. Students six month post-training reported a rise in confidence (1.94 to 2.45; p < 0.01) and knowledge (2.27 to 2.76; p < 0.01) regarding MOUD. They also reported their plans to apply for the buprenorphine waiver once licensed and reported being more likely to prescribe buprenorphine for OUD as a result of the training (mean = 3.35; SD = 1.36; 0 = extremely unlikely to 5 = extremely likely). Conclusions: We successfully implemented a DATA 2000 waiver training as a mandatory requirement for the medical school curriculum. Further studies are needed to determine optimal timing, best format, and frequency of reinforcement of MOUD educational content across the undergraduate and graduate medical education continuum.

Entities:  

Keywords:  Buprenorphine; curriculum; medical student; medication-assisted treatment; opioid use disorder; training; waiver

Year:  2020        PMID: 32031914     DOI: 10.1080/08897077.2019.1692323

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  6 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  Cross-training needs among community-based clinicians in HIV and substance use.

Authors:  Kasey Claborn; Kelli Scott; Sara J Becker
Journal:  BMC Med Educ       Date:  2022-08-19       Impact factor: 3.263

3.  Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment.

Authors:  Neha Balapal; Amala Ankem; Saishravan Shyamsundar; Shuhan He
Journal:  JMIR Med Educ       Date:  2022-07-18

4.  Developing and validating an opioid overdose prevention and response curriculum for undergraduate medical education.

Authors:  Tabitha E Moses; Jessica L Moreno; Mark K Greenwald; Eva Waineo
Journal:  Subst Abus       Date:  2021-07-02       Impact factor: 3.716

5.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

6.  Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.

Authors:  Nicola R Jones; Suzanne Nielsen; Michael Farrell; Robert Ali; Anthony Gill; Sarah Larney; Louisa Degenhardt
Journal:  Drug Alcohol Depend       Date:  2020-12-19       Impact factor: 4.492

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.